Astec Lifesciences achieved an EBITDA break-even in FY26, a significant turnaround from a loss. Sales grew 17.5%, and net loss reduced. Promoter Godrej Agrovet increased its stake.
Astec Lifesciences Achieves EBITDA Break-Even, Cuts Net Loss in FY26
Astec Lifesciences reported its financial results for the fiscal year 2025-26, marking a notable operational turnaround. The company moved from an EBITDA loss in the previous year to achieve break-even, driven by improved capacity utilization and a better product mix. Sales increased by 17.5% year-on-year to ₹448.15 crore.
Reader Takeaway: Operational turnaround to EBITDA break-even; net loss reduction continues.
What just happened
Astec Lifesciences announced its fiscal year 2025-26 results, showing a significant improvement in operational performance. The company reported an EBITDA of ₹0.54 crore, a stark contrast to the ₹60.58 crore loss in FY 2024-25. Total sales grew by 17.5% to ₹448.15 crore, and the net loss after tax was reduced to ₹80.88 crore from ₹134.71 crore in the prior year.
Why this matters
This marks a crucial step in the company's recovery, indicating better cost management and operational efficiency. The reduction in net loss, coupled with a 17.5% sales increase and gross margin expansion to 33.4%, suggests a positive trajectory despite the overall net loss. The increased promoter stake by Godrej Agrovet also signals confidence.
The backstory
The company has been focused on operational recovery. In FY 2024-25, it reported an EBITDA loss of ₹60.58 crore and a net loss of ₹134.71 crore. This fiscal year's results show a significant shift towards profitability, supported by a 40.6% rise in domestic sales and a 6.7% increase in export sales.
What changes now
The company has strengthened its capital position through a Rights Issue. Leadership changes, including a new Chairperson and CFO, have taken effect. The focus will now be on sustaining this operational improvement, growing sales, and achieving net profitability. The support from holding company Godrej Agrovet is a key factor.
Risks to watch
Key concerns include volatility in raw material prices due to overseas supply chain dependencies and the sensitivity of export revenues to global trade tensions and tariffs.
Peer comparison
Astec Lifesciences operates in the agrochemical sector, which is subject to cyclical demand and regulatory changes. Specific peer comparisons are not provided in the filing but are typically companies involved in API manufacturing and contract research and manufacturing services (CRAMS) within the pharmaceutical and agrochemical industries.
Context metrics (time-bound)
- Sales for FY 2025-26 stood at ₹448.15 crore, up from ₹381.30 crore in FY 2024-25.
- EBITDA improved from (₹60.58) crore in FY 2024-25 to ₹0.54 crore in FY 2025-26.
- Net loss reduced from (₹134.71) crore in FY 2024-25 to (₹80.88) crore in FY 2025-26.
- Gross margin expanded to 33.4% in FY 2025-26 from 22.1% in FY 2024-25.
- Domestic sales grew 40.6% YoY, and export sales grew 6.7% YoY in FY 2025-26.
- Godrej Agrovet's stake increased from 64.75% to 67.03% between March 2025 and March 2026.
What to track next
Investors should monitor sustained EBITDA growth, progress towards net profitability, the performance of the CDMO and Enterprise segments, and the impact of new leadership on strategic initiatives.